Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Targeting RAGE in sepsis.

Marieke A D van Zoelen, Tom van der Poll

    Critical Care (London, England)
    |February 8, 2008
    PubMed
    Summary
    This summary is machine-generated.

    Receptor of advanced glycation endproducts (RAGE) is implicated in sepsis-induced inflammation. Further research is needed to address open issues before anti-RAGE therapies can be used in clinical trials for sepsis.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Incidence, Predictors, and Outcomes of New-Onset Atrial Fibrillation in Critically Ill Patients with Sepsis. A Cohort Study.

    American journal of respiratory and critical care medicine·2016
    Same author

    Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis.

    American journal of respiratory and critical care medicine·2016
    Same author

    Chronic healthcare expenditure in survivors of sepsis in the intensive care unit.

    Intensive care medicine·2016
    Same author

    Granzyme A impairs host defense during Streptococcus pneumoniae pneumonia.

    American journal of physiology. Lung cellular and molecular physiology·2016
    Same author

    Antibiotic-induced gut microbiota disruption during human endotoxemia: a randomised controlled study.

    Gut·2016
    Same author

    High endogenous activated protein C levels attenuates bleomycin-induced pulmonary fibrosis.

    Journal of cellular and molecular medicine·2016
    Same journal

    Correction: VExUS score: optimizing its use in perioperative and critical care management.

    Critical care (London, England)·2026
    Same journal

    Optimizing β-lactam antibiotics with the highest concentration-for continuous infusion reduce carbon footprint in intensive care.

    Critical care (London, England)·2026
    Same journal

    Physiological and clinical effects of selected airway clearance techniques in mechanically ventilated adult ICU patients: a systematic review and synthesis without meta-analysis.

    Critical care (London, England)·2026
    Same journal

    How we use the neurological pupil index (NPi).

    Critical care (London, England)·2026
    Same journal

    45th International Symposium on Intensive Care & Emergency Medicine.

    Critical care (London, England)·2026
    Same journal

    High-resolution monitoring reveals fragmented 24-hour light exposure in intensive care units.

    Critical care (London, England)·2026
    See all related articles

    Area of Science:

    • Immunology
    • Critical Care Medicine
    • Molecular Biology

    Background:

    • The receptor of advanced glycation endproducts (RAGE) is a key mediator in inflammatory responses.
    • RAGE activation leads to sustained signaling through multiple inflammatory pathways.
    • Recent evidence suggests RAGE as a potential therapeutic target for sepsis.

    Discussion:

    • Sepsis involves complex inflammatory cascades where RAGE plays a significant role.
    • Targeting RAGE presents a promising avenue for novel sepsis treatments.
    • Several critical questions remain unanswered regarding RAGE's precise role in sepsis.

    Key Insights:

    • RAGE is a multiligand receptor implicated in sustained inflammatory pathway activation.
    • RAGE is a potential therapeutic target for managing sepsis.

    Related Experiment Videos

  • Translating anti-RAGE strategies into clinical sepsis trials requires addressing outstanding issues.

    • Outlook:

    • Further investigation into RAGE's specific mechanisms in sepsis is essential.
    • Pre-clinical research must resolve current challenges before human trials.
    • Developing effective anti-RAGE therapies could revolutionize sepsis management.